Analysts Issue Forecasts for OTLK FY2026 Earnings

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Brookline Capital Management decreased their FY2026 earnings per share estimates for Outlook Therapeutics in a report released on Tuesday, May 27th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings of $0.50 per share for the year, down from their prior forecast of $0.54. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($2.27) per share.

Outlook Therapeutics (NASDAQ:OTLK) last released its earnings results on Thursday, May 15th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.15.

A number of other equities research analysts also recently weighed in on OTLK. Guggenheim reissued a “buy” rating on shares of Outlook Therapeutics in a research report on Tuesday, May 20th. Ascendiant Capital Markets decreased their price objective on Outlook Therapeutics from $33.00 to $24.00 and set a “buy” rating on the stock in a report on Monday, February 24th. Chardan Capital restated a “neutral” rating and set a $3.00 price objective on shares of Outlook Therapeutics in a research report on Tuesday, February 18th. Finally, HC Wainwright cut their target price on Outlook Therapeutics from $30.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.20.

Outlook Therapeutics Stock Performance

Shares of OTLK opened at $1.85 on Thursday. The company has a 50-day simple moving average of $1.48 and a 200-day simple moving average of $1.90. The firm has a market capitalization of $62.10 million, a P/E ratio of -0.25 and a beta of 0.39. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $9.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in shares of Outlook Therapeutics by 1,329.6% in the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock valued at $355,000 after purchasing an additional 174,896 shares during the period. Bank of New York Mellon Corp boosted its stake in Outlook Therapeutics by 44.8% in the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company’s stock valued at $56,000 after buying an additional 9,211 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Outlook Therapeutics in the fourth quarter valued at $246,000. Russell Investments Group Ltd. raised its stake in Outlook Therapeutics by 34,936.7% during the fourth quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company’s stock worth $32,000 after acquiring an additional 17,119 shares in the last quarter. Finally, Commonwealth Equity Services LLC acquired a new position in Outlook Therapeutics during the fourth quarter worth $48,000. Institutional investors own 11.20% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.